Medigen Biotechnology (3176) - Total Liabilities
Based on the latest financial reports, Medigen Biotechnology (3176) has total liabilities worth NT$1.45 Billion TWD (≈ $45.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Medigen Biotechnology (3176) net asset momentum to track the company's year-over-year net asset growth rate.
Medigen Biotechnology - Total Liabilities Trend (2003–2024)
This chart illustrates how Medigen Biotechnology's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Medigen Biotechnology generate to measure how efficiently the company converts operating cash flow to free cash.
Medigen Biotechnology Competitors by Total Liabilities
The table below lists competitors of Medigen Biotechnology ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bassett Furniture Industries
NASDAQ:BSET
|
USA | $158.71 Million |
|
Kross Ltd
NSE:KROSS
|
India | Rs1.49 Billion |
|
Fu Chun Shin Machinery Manufacture Co Ltd
TWO:6603
|
Taiwan | NT$5.75 Billion |
|
Golden Long Teng Development Co Ltd
TWO:3188
|
Taiwan | NT$7.84 Billion |
|
Tenaya Therapeutics Inc
NASDAQ:TNYA
|
USA | $22.11 Million |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
USA | $959.00 Million |
|
Malaysia Marine and Heavy Engineering Holdings Bhd
KLSE:5186
|
Malaysia | RM1.85 Billion |
|
Thessaloniki Water Supply & Sewerage Co S.A
AT:EYAPS
|
Greece | €55.08 Million |
Liability Composition Analysis (2003–2024)
This chart breaks down Medigen Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Medigen Biotechnology.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medigen Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medigen Biotechnology (2003–2024)
The table below shows the annual total liabilities of Medigen Biotechnology from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.67 Billion ≈ $52.69 Million |
-52.62% |
| 2023-12-31 | NT$3.53 Billion ≈ $111.22 Million |
+0.54% |
| 2022-12-31 | NT$3.51 Billion ≈ $110.62 Million |
+98.00% |
| 2021-12-31 | NT$1.77 Billion ≈ $55.87 Million |
+7.29% |
| 2020-12-31 | NT$1.65 Billion ≈ $52.08 Million |
-22.89% |
| 2019-12-31 | NT$2.14 Billion ≈ $67.53 Million |
+29.34% |
| 2018-12-31 | NT$1.66 Billion ≈ $52.21 Million |
-1.97% |
| 2017-12-31 | NT$1.69 Billion ≈ $53.26 Million |
+31.60% |
| 2016-12-31 | NT$1.28 Billion ≈ $40.47 Million |
+24.69% |
| 2015-12-31 | NT$1.03 Billion ≈ $32.46 Million |
+28.08% |
| 2014-12-31 | NT$804.40 Million ≈ $25.34 Million |
+254.62% |
| 2013-12-31 | NT$226.84 Million ≈ $7.15 Million |
+21.68% |
| 2012-12-31 | NT$186.42 Million ≈ $5.87 Million |
-37.61% |
| 2011-12-31 | NT$298.81 Million ≈ $9.41 Million |
+382.86% |
| 2010-12-31 | NT$61.88 Million ≈ $1.95 Million |
-24.77% |
| 2009-12-31 | NT$82.25 Million ≈ $2.59 Million |
-41.80% |
| 2008-12-31 | NT$141.33 Million ≈ $4.45 Million |
+13.66% |
| 2007-12-31 | NT$124.35 Million ≈ $3.92 Million |
+65.89% |
| 2006-12-31 | NT$74.96 Million ≈ $2.36 Million |
+44.75% |
| 2005-12-31 | NT$51.78 Million ≈ $1.63 Million |
+83.22% |
| 2004-12-31 | NT$28.26 Million ≈ $890.47K |
-74.34% |
| 2003-12-31 | NT$110.16 Million ≈ $3.47 Million |
-- |
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more